Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2026-02-26 @ 12:03 PM
Study NCT ID:
NCT02453594
Status:
COMPLETED
Last Update Posted:
2024-10-29
First Post:
2015-05-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-10
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-18
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-21
First Submit QC Date:
None
Study First Post Date:
2015-05-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2024-09-12
Results First Submit QC Date:
None
Results First Post Date:
2024-10-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-28
Last Update Post Date:
2024-10-29
Last Update Post Date Type:
ACTUAL